SCHEMBL5740296

SCHEMBL5740296

CN(C(=O)C(C)(C)c1cc(C(F)(F)F)cc(C(F)(F)F)c1)c1ccc(Cl)cc1C(=O)c1ccccc1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TACR1 P25103 16/20 0.60
GABRP O00591 1/20 0.57
GABRD O14764 1/20 0.57
GABRA1 P14867 1/20 0.57
GABRB1 P18505 1/20 0.57
GABRG2 P18507 1/20 0.57
GABRB3 P28472 1/20 0.57
GABRA5 P31644 1/20 0.57
GABRA3 P34903 1/20 0.57
GABRA2 P47869 1/20 0.57
GABRB2 P47870 1/20 0.57
GABRA4 P48169 1/20 0.57
GABRE P78334 1/20 0.57
GABRA6 Q16445 1/20 0.57
GABRG1 Q8N1C3 1/20 0.57
GABRG3 Q99928 1/20 0.57
GABRQ Q9UN88 1/20 0.57
TACR3 P29371 10/20 0.48
C5AR1 P21730 1/20 0.47
P2RX1 P51575 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5741035 0.91 TACR1 (0.57) TACR1GABRPGABRDGABRA1GABRB1
SCHEMBL5740755 0.87 TACR1 (0.66) TACR1TACR3
SCHEMBL5740693 0.86 TACR1 (0.56) TACR1GABRPGABRDGABRA1GABRB1
SCHEMBL5740978 0.85 TACR1 (0.55) TACR1GABRPGABRDGABRA1GABRB1
SCHEMBL5742325 0.82 GABRP (0.54) TACR1GABRPGABRDGABRA1GABRB1
SCHEMBL5742326 0.82 GABRP (0.54) TACR1GABRPGABRDGABRA1GABRB1
SCHEMBL5739710 0.81 TACR1 (0.61) TACR1TACR3
SCHEMBL11844102 0.81 GABRP (0.67) GABRPGABRDGABRA1GABRB1GABRG2
SCHEMBL5741798 0.79 TACR1 (0.64) TACR1
SCHEMBL11037113 0.78 GABRP (0.73) GABRPGABRDGABRA1GABRB1GABRG2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1157006-B1 PHENYL- AND PYRIDINYL DERIVATIVES AS NEUROKININ 1 ANTAGONISTS HOFFMANN LA ROCHE (CH) 2006-10-25 EP disclosed
CN-1131212-C Phenyl-and pyridinyl derivatives HOFFMANN LA ROCHE (CH) 2003-12-17 CN disclosed
US-6596773-B2 Central nervous system disorders HOFFMANN-LA ROCHE INC. 2003-07-22 US disclosed
US-20020111367-A1 Phenyl substituted pyridine and benzene derivatives BOS MICHAEL (CA) 2002-08-15 US disclosed
US-6407111-B1 SUBSTANCE P OR NEUROKININ 1 ANTAGONISTS; ANTIINFLAMMATORY, ANTIDEPRESSANT, ANTIARTHRITIC, AND ANTIASTHMATIC AGENTS; PARKINSON*S DISEASE, INFLAMMATORY BOWEL DISEASE, CENTRAL NERVOUS SYSTEM AND RHEUMATIC DISORDERS HOFFMANN-LA ROCHE INC. 2002-06-18 US disclosed
CN-1341101-A Phenyl-and pyridinyl derivatives HOFFMANN LA ROCHE (CH) 2002-03-20 CN disclosed
EP-1157006-A2 PHENYL- AND PYRIDINYL DERIVATIVES AS NEUROKININ 1 ANTAGONISTS F. HOFFMANN-LA ROCHE AG (CH) 2001-11-28 EP disclosed
WO-2000050398-A2 PHENYL- AND PYRIDINYL DERIVATIVES AS NEUROKININ 1 ANTAGONISTS F. HOFFMANN-LA ROCHE AG (CH) 2000-08-31 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020111367-A1 Phenyl substituted pyridine and benzene derivatives BDKRB1, BAK1, PBK TACR1 16/4885GABRP 113/4885GABRD 673/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.